SMYD3 and cancer: Wang et al. demonstrated an epigenetic switch of cancer stem cells (CSCs) through SMYD3-dependent activation of the stem cell transcription factor Achaete-scute homolog 2 (ASCL2) in gastric carcinoma [53].